AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

From seasonal irritations to serious health indicators, medical experts explain the hidden meanings behind different types of ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

Maybe you've been in a room recently with someone who's coughing, but they say "I promise it's not COVID." While it's important to still be cautious about COVID-19, there are other viral ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population ...

HIV is spread by bodily fluids such as blood, breast milk or semen. It gradually weakens the body’s immune system and makes ...

If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...